Publications Archive - KalVista Pharmaceuticals

Showing 3 out of 3

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Longhurst HJ, Smith MD, Yea CM, Audhya PK

ASCIA 2022

Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

Aygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD

EAACI 2022

Agreement of Patient Global Impression of Change With Attack Resolution or Use of Rescue Medication in Patients With Hereditary Angioedema

Audhya P, Williams P, Yea C, Cohn D

AAAAI 2022

About

Science

Pipeline

Careers

Contact